{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:53:50Z","timestamp":1761515630412,"version":"build-2065373602"},"reference-count":79,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.4158\/ep09385.ra","type":"journal-article","created":{"date-parts":[[2010,3,30]],"date-time":"2010-03-30T21:04:40Z","timestamp":1269983080000},"page":"677-685","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Treatment of Thyroid-Associated Orbitopathy With Rituximab\u2014A Novel Therapy for an Old Disease: Case Report and Literature Review"],"prefix":"10.1016","volume":"16","author":[{"given":"Sara","family":"Madaschi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Formenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vito","family":"Lampasona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania Bianchi","family":"Marzoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Cammarata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Letterio S.","family":"Politi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Bazzigaluppi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Scavini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Bosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Lanzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP09385.RA_bb0010","first-page":"747","article-title":"Graves' ophthalmopathy: current concepts regarding pathogenesis and management","volume":"14","author":"Burch","year":"1993","journal-title":"Endocr Rev"},{"key":"10.4158\/EP09385.RA_bb0015","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1089\/thy.1997.7.885","article-title":"Quality of life in patients with Graves' ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument","volume":"7","author":"Gerding","year":"1997","journal-title":"Thyroid"},{"key":"10.4158\/EP09385.RA_bb0020","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nrendo.2009.61","article-title":"Graves orbitopathy: a perspective","volume":"5","author":"Perros","year":"2009","journal-title":"Nat Rev Endocrinol"},{"key":"10.4158\/EP09385.RA_bb0025","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1530\/EJE-07-0666","article-title":"Consensus statement of the European Group on Graves' Orbitopathy (EUGOGO) on management of GO","volume":"158","author":"Bartalena","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP09385.RA_bb0030","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Graves' ophthalmopathy","volume":"362","author":"Bahn","year":"2010","journal-title":"N Engl J Med"},{"key":"10.4158\/EP09385.RA_bb0035","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1210\/en.2005-1018","article-title":"T helper type 1 and type 2 cytokines exert divergent influence on the induction of prostaglandin E2 and hyaluronan synthesis by interleukin-1beta in orbital fibroblasts: implications for the pathogenesis of thyroid-associated ophthalmopathy","volume":"147","author":"Han","year":"2006","journal-title":"Endocrinology"},{"key":"10.4158\/EP09385.RA_bb0040","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1055\/s-0029-1220935","article-title":"Current insights into the pathogenesis of Graves' orbitopathy","volume":"41","author":"Eckstein","year":"2009","journal-title":"Horm Metab Res"},{"key":"10.4158\/EP09385.RA_bb0045","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1210\/jc.2009-0376","article-title":"Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis","volume":"94","author":"Stiebel-Kalish","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09385.RA_bb0050","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1530\/eje.1.02119","article-title":"Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression","volume":"154","author":"Salvi","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP09385.RA_bb0055","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1530\/eje.1.02325","article-title":"Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study","volume":"156","author":"Salvi","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP09385.RA_bb0060","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.clim.2008.12.005","article-title":"Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates","volume":"131","author":"Salvi","year":"2009","journal-title":"Clin Immunol"},{"key":"10.4158\/EP09385.RA_bb0065","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1530\/eje.1.02140","article-title":"The rationale for B lymphocyte depletion in Graves' disease: monoclonal anti-CD20 antibody therapy as a novel treatment option","volume":"154","author":"El Fassi","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP09385.RA_bb0070","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1089\/thy.2006.16.709","article-title":"Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion","volume":"16","author":"El Fassi","year":"2006","journal-title":"Thyroid"},{"key":"10.4158\/EP09385.RA_bb0075","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1210\/jc.2007-1238","article-title":"Evidence of intrathyroidal B-lymphocyte depletion after rituximab therapy in a patient with Graves' disease","volume":"92","author":"El Fassi","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09385.RA_bb0080","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1210\/jc.2006-2388","article-title":"B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study","volume":"92","author":"El Fassi","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09385.RA_bb0085","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.clim.2008.09.007","article-title":"Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies","volume":"130","author":"El Fassi","year":"2009","journal-title":"Clin Immunol"},{"key":"10.4158\/EP09385.RA_bb0090","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ophtha.2009.05.029","article-title":"Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy","volume":"117","author":"Khanna","year":"2010","journal-title":"Ophthalmology"},{"key":"10.4158\/EP09385.RA_bb0095","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/jnnp.2004.051144","article-title":"Treatment of stiff person syndrome with rituximab","volume":"76","author":"Baker","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.4158\/EP09385.RA_bb0100","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1212\/01.wnl.0000313840.27060.bf","article-title":"Invited article: inhibition of B cell functions; implications for neurology","volume":"70","author":"Dalakas","year":"2008","journal-title":"Neurology"},{"key":"10.4158\/EP09385.RA_bb0105","unstructured":"Clinical Trials. Gov: A Service of the U. S. National Institutes of Health. Rituximab to treat stiff person syndrome. January 28, 2010. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00091897"},{"key":"10.4158\/EP09385.RA_bb0110","first-page":"168","article-title":"Management of Graves' ophthalmopathy: reality and perspectives","volume":"21","author":"Bartalena","year":"2000","journal-title":"Endocr Rev"},{"key":"10.4158\/EP09385.RA_bb0115","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1210\/jc.2005-0148","article-title":"Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy","volume":"90","author":"Kahaly","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09385.RA_bb0120","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1034\/j.1600-0420.2002.800316.x","article-title":"High dose intravenous methylprednisolone pulse therapy versus oral prednisone for thyroid-associated ophthalmopathy","volume":"80","author":"Kauppinen-M\u00e4kelin","year":"2002","journal-title":"Acta Ophthalmol Scand"},{"key":"10.4158\/EP09385.RA_bb0125","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1530\/EJE-07-0558","article-title":"Methylprednisolone pulse therapy for patients with moderately severe Graves' orbitopathy: a prospective, randomized, placebo-controlled study","volume":"158","author":"van Geest","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP09385.RA_bb0130","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/BF03343835","article-title":"High-dose intravenous corticosteroid therapy for Graves' ophthalmopathy","volume":"24","author":"Macchia","year":"2001","journal-title":"J Endocrinol Invest"},{"key":"10.4158\/EP09385.RA_bb0135","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199801083380201","article-title":"Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy","volume":"338","author":"Bartalena","year":"1998","journal-title":"N Engl J Med"},{"key":"10.4158\/EP09385.RA_bb0140","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM198911163212001","article-title":"Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism","volume":"321","author":"Bartalena","year":"1989","journal-title":"N Engl J Med"},{"key":"10.4158\/EP09385.RA_bb0145","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/105072504774193276","article-title":"Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy","volume":"14","author":"Marin\u00f3","year":"2004","journal-title":"Thyroid"},{"key":"10.4158\/EP09385.RA_bb0150","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1089\/thy.2006.0267","article-title":"Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy","volume":"17","author":"Le Moli","year":"2007","journal-title":"Thyroid"},{"key":"10.4158\/EP09385.RA_bb0155","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nrendo.2009.222","article-title":"Therapy: evidence-based treatment of Graves ophthalmopathy","volume":"5","author":"Wiersinga","year":"2009","journal-title":"Nat Rev Endocrinol"},{"key":"10.4158\/EP09385.RA_bb0160","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S1043-2760(02)00622-7","article-title":"Graves' ophthalmopathy: a rational approach to treatment","volume":"13","author":"Wiersinga","year":"2002","journal-title":"Trends Endocrinol Metab"},{"key":"10.4158\/EP09385.RA_bb0165","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0140-6736(00)02165-6","article-title":"Radiotherapy for Graves' orbitopathy: randomised placebo-controlled study","volume":"355","author":"Mourits","year":"2000","journal-title":"Lancet"},{"key":"10.4158\/EP09385.RA_bb0170","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1210\/jc.2003-030809","article-title":"A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy","volume":"89","author":"Prummel","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09385.RA_bb0175","first-page":"1306","article-title":"A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy [published correction appears in","volume":"111","author":"Gorman","year":"2004","journal-title":"Ophthalmology"},{"key":"10.4158\/EP09385.RA_bb0180","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1089\/105072502753600223","article-title":"Orbital radiotherapy for Graves' ophthalmopathy","volume":"12","author":"Bartalena","year":"2002","journal-title":"Thyroid"},{"key":"10.4158\/EP09385.RA_bb0185","first-page":"102","article-title":"Lowversus high-dose radiotherapy for Graves' ophthalmopathy: a randomized, single blind trial","volume":"85","author":"Kahaly","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09385.RA_bb0190","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1210\/jcem-37-2-276","article-title":"Supervoltage orbital radiotherapy for Graves' ophthalmopathy","volume":"37","author":"Donaldson","year":"1973","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09385.RA_bb0195","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1210\/jc.2003-030260","article-title":"Long-term safety of orbital radiotherapy for Graves' ophthalmopathy","volume":"88","author":"Marcocci","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09385.RA_bb0200","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0360-3016(01)01699-6","article-title":"Long-term results of irradiation for patients with progressive Graves' ophthalmopathy","volume":"51","author":"Marquez","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.4158\/EP09385.RA_bb0205","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.ophtha.2003.12.054","article-title":"Orbital irradiation for Graves' ophthalmopathy: is it safe? A long-term followup study","volume":"111","author":"Wakelkamp","year":"2004","journal-title":"Ophthalmology"},{"key":"10.4158\/EP09385.RA_bb0210","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1001\/archopht.121.5.652","article-title":"Retinal microvascular abnormalities in patients treated with external radiation for Graves ophthalmopathy [published correction appears in","volume":"121","author":"Robertson","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.4158\/EP09385.RA_bb0215","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S0002-9394(14)76869-2","article-title":"Radiation retinopathy after standard radiotherapy for thyroid-related ophthalmopathy","volume":"112","author":"Miller","year":"1991","journal-title":"Am J Ophthalmol"},{"key":"10.4158\/EP09385.RA_bb0220","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bjo.75.10.629","article-title":"Synergism between diabetic and radiation retinopathy: case report and review","volume":"75","author":"Viebahn","year":"1991","journal-title":"Br J Ophthalmol"},{"key":"10.4158\/EP09385.RA_bb0225","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/ncpendmet0497","article-title":"Management of Graves' ophthalmopathy","volume":"3","author":"Wiersinga","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.4158\/EP09385.RA_bb0230","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2265.2005.02345.x","article-title":"Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves' ophthalmopathy? A randomized controlled trial","volume":"63","author":"Wakelkamp","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.4158\/EP09385.RA_bb0235","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ajo.2005.04.023","article-title":"The removal of the deep lateral wall in orbital decompression: its contribution to exophthalmos reduction and influence on consecutive diplopia","volume":"140","author":"Baldeschi","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.4158\/EP09385.RA_bb0240","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.ophtha.2005.10.060","article-title":"Early versus late orbital decompression in Graves' orbitopathy: a retrospective study in 125 patients","volume":"113","author":"Baldeschi","year":"2006","journal-title":"Ophthalmology"},{"key":"10.4158\/EP09385.RA_bb0245","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0161-6420(02)01994-2","article-title":"Clinical features and treatment of late enophthalmos after orbital decompression: a condition suggesting cause for idiopathic \"imploding antrum\" (silent sinus) syndrome","volume":"110","author":"Rose","year":"2003","journal-title":"Ophthalmology"},{"key":"10.4158\/EP09385.RA_bb0250","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/sj.eye.6702381","article-title":"Postural visual obscurations in patients with inactive thyroid eye disease: a variant of \"hydraulic\" disease","volume":"20","author":"Rose","year":"2006","journal-title":"Eye (Lond)"},{"key":"10.4158\/EP09385.RA_bb0255","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.ophtha.2006.10.036","article-title":"Reactivation of Graves' orbitopathy after rehabilitative orbital decompression","volume":"114","author":"Baldeschi","year":"2007","journal-title":"Ophthalmology"},{"key":"10.4158\/EP09385.RA_bb0260","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/BF03344124","article-title":"Slow-release lanreotide in Graves' ophthalmopathy: a double-blind randomized, placebo-controlled clinical trial","volume":"29","author":"Chang","year":"2006","journal-title":"J Endocrinol Invest"},{"key":"10.4158\/EP09385.RA_bb0265","doi-asserted-by":"crossref","first-page":"5910","DOI":"10.1210\/jc.2004-0697","article-title":"Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy","volume":"89","author":"Dickinson","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09385.RA_bb0270","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1210\/jc.2006-1105","article-title":"Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy","volume":"91","author":"Stan","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09385.RA_bb0275","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1210\/jc.2004-1334","article-title":"Octreotide (longacting release formulation) treatment in patients with Graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study","volume":"90","author":"W\u00e9meau","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09385.RA_bb0280","first-page":"8","article-title":"Azathioprine in the treatment of thyroid-associated ophthalmopathy","volume":"122","author":"Perros","year":"1990","journal-title":"Acta Endocrinol (Copenh)"},{"key":"10.4158\/EP09385.RA_bb0285","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2362.1986.tb01016.x","article-title":"Cyclosporin and prednisone v. prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study","volume":"16","author":"Kahaly","year":"1986","journal-title":"Eur J Clin Invest"},{"key":"10.4158\/EP09385.RA_bb0290","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1089\/105072502753600214","article-title":"Medical treatment for thyroidassociated ophthalmopathy","volume":"12","author":"Perros","year":"2002","journal-title":"Thyroid"},{"key":"10.4158\/EP09385.RA_bb0295","first-page":"13","article-title":"Ciamexone in endocrine orbitopathy: a randomized double-blind, placebo-controlled study","volume":"122","author":"Kahaly","year":"1990","journal-title":"Acta Endocrinol (Copenh)"},{"key":"10.4158\/EP09385.RA_bb0300","first-page":"13","article-title":"High-dose intravenous immunoglobulin treatment in Graves' ophthalmopathy","volume":"126","author":"Antonelli","year":"1992","journal-title":"Acta Endocrinol (Copenh)"},{"key":"10.4158\/EP09385.RA_bb0305","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1046\/j.1365-2249.1996.d01-854.x","article-title":"Randomized trial of intravenous immunoglobulins versus prednisolone in Graves' ophthalmopathy","volume":"106","author":"Kahaly","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"10.4158\/EP09385.RA_bb0310","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S0002-9394(00)00359-7","article-title":"Antioxidant agents in the treatment of Graves' ophthalmopathy","volume":"129","author":"Bouzas","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"10.4158\/EP09385.RA_bb0315","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1210\/jcem.82.6.9995","article-title":"Beneficial effect of pentoxifylline on thyroid associated ophthalmopathy (TAO)*: a pilot study [published correction appears in","volume":"82","author":"Balazs","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09385.RA_bb0320","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/112067210401400401","article-title":"Pentoxifylline (PTX)\u2014an alternative treatment in Graves' ophthalmopathy (inactive phase): assessment by a disease specific quality of life questionnaire and by exophthalmometry in a prospective randomized trial","volume":"14","author":"Finamor","year":"2004","journal-title":"Eur J Ophthalmol"},{"key":"10.4158\/EP09385.RA_bb0325","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1136\/bjo.85.10.1220","article-title":"A role for methotrexate in the management of non-infectious orbital inflammatory disease","volume":"85","author":"Smith","year":"2001","journal-title":"Br J Ophthalmol"},{"key":"10.4158\/EP09385.RA_bb0330","doi-asserted-by":"crossref","first-page":"422","DOI":"10.4158\/EP.14.4.422","article-title":"Use of methotrexate to treat isolated Graves ophthalmopathy developing years after thyroidectomy and iodine 131 treatment of papillary thyroid cancer","volume":"14","author":"Sanyal","year":"2008","journal-title":"Endocr Pract"},{"key":"10.4158\/EP09385.RA_bb0335","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/art.10947","article-title":"Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy","volume":"48","author":"Silverman","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.4158\/EP09385.RA_bb0340","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"10.4158\/EP09385.RA_bb0345","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.20430","article-title":"B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab","volume":"50","author":"Looney","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.4158\/EP09385.RA_bb0350","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood.V98.4.952","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura","volume":"98","author":"Stasi","year":"2001","journal-title":"Blood"},{"key":"10.4158\/EP09385.RA_bb0355","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMoa0904452","article-title":"Rituximab, B-lymphocyte depletion, and preservation of beta-cell function","volume":"361","author":"Pescovitz","year":"2009","journal-title":"N Engl J Med"},{"key":"10.4158\/EP09385.RA_bb0360","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s12016-007-8024-3","article-title":"Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves' ophthalmopathy","volume":"34","author":"Bonara","year":"2008","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.4158\/EP09385.RA_bb0365","first-page":"169","article-title":"Antigen processing by autoreactive B cells promotes determinant spreading","volume":"2","author":"Dai","year":"2005","journal-title":"Cell Mol Immunol"},{"key":"10.4158\/EP09385.RA_bb0370","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1530\/EJE-08-0084","article-title":"Rituximab in relapsing Graves' disease, a phase II study","volume":"159","author":"Heemstra","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP09385.RA_bb0375","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1186\/ar1739","article-title":"B cell non-Hodgkin's lymphoma: rituximab safety experience","volume":"7","author":"Mohrbacher","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.4158\/EP09385.RA_bb0380","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdg175","article-title":"An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab","volume":"14","author":"Boye","year":"2003","journal-title":"Ann Oncol"},{"key":"10.4158\/EP09385.RA_bb0385","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1002\/art.24906","article-title":"Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis","volume":"60","author":"Fleischmann","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.4158\/EP09385.RA_bb0390","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1365-2265.2009.03762.x","article-title":"Failure of rituximab treatment in a case of severe thyroid ophthalmopathy unresponsive to steroids","volume":"72","author":"Krassas","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.4158\/EP09385.RA_bb0395","unstructured":"Clinical Trials. Gov: A Service of the U. S. National Institutes of Health. Trial of rituximab for Graves' ophthalmopathy. August 20, 2009. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00595335"},{"key":"10.4158\/EP09385.RA_bb0400","unstructured":"Clinical Trials. Gov: A Service of the U. S. National Institutes of Health. Rituximab treatment of Graves' dysthyroid ophthalmopathy. September 18, 2007. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00424151"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2040816X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2040816X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/K470R6625Q780261.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:51:05Z","timestamp":1761515465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X2040816X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":79,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["S1530891X2040816X"],"URL":"https:\/\/doi.org\/10.4158\/ep09385.ra","relation":{},"ISSN":["1530-891X"],"issn-type":[{"type":"print","value":"1530-891X"}],"subject":[],"published":{"date-parts":[[2010,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Thyroid-Associated Orbitopathy With Rituximab\u2014A Novel Therapy for an Old Disease: Case Report and Literature Review","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP09385.RA","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}